FDA clears ENV-308 for Phase 1 as Enveda doses first patient and appoints former Novo Nordisk executive to lead metabolic strategy.
Clinical stage company Enveda has reached a pivotal point in its metabolic disease program, announcing US Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for ENV-308, alongside the dosing of the first patient in a Phase 1 clinical trial.
The Boulder, Colorado-based clinical-stage biotech is also strengthening its leadership bench with the appointment of former Novo Nordisk Co-Founder and Head of the Transformational Prevention Unit, Nadeem Sarwar, PhD, MPharm, MPhil, as Senior Vice President and Global Head of Disease Prevention and Metabolic Disease Strategy.
Together, the developments signal Enveda’s intent to move beyond short-term weight-loss narratives toward durable, scalable solutions for obesity and metabolic health, an area that is drawing intense interest from investors, healthcare systems and policymakers worldwide.
ENV-308 is a first-in-class, once-daily oral small molecule being developed for chronic weight management [1]. Unlike injectable therapies that dominate today’s obesity market, ENV-308 is designed to support long-term maintenance – an unmet need as many patients struggle with tolerability, adherence, or sustaining benefits after initial weight loss.
Enveda positions ENV-308 as a therapy that can be used across the full continuum of care, from earlier intervention through long-term maintenance following GLP-1 induction or lifestyle changes.
The company likens this strategy to the role statins came to play in cardiovascular disease: practical, durable and broadly deployable.
“Obesity is a chronic, multi-system disease, and long-term success at population scale will require therapies engineered for durability, tolerability, and everyday practicality,” said Dr Viswa Colluru, Enveda’s founder and CEO.
Colluru noted that the unlocking of metabolic longevity is considered humanity’s next moonshot. This is not viewed as a matter of simply losing weight; rather, it is seen as the design of a future where disease is prevented before it starts, vitality is preserved and a healthy lifespan is extended at the population scale.
“ENV-308 is our first step toward that reality. With the clearance of our IND and the dosing of our first patient, we are moving closer to providing a practical, oral solution for sustainable metabolic health,” he added.
The Phase 1 study, now underway in the US, is designed to assess safety, tolerability, pharmacokinetics – how the drug moves through the body – and early pharmacodynamic signals or how it affects metabolic processes.
Preclinical data supporting the program point to a profile optimized for chronic use. In non-clinical studies, ENV-308 demonstrated weight loss while preserving muscle mass, a key marker of so-called “high-quality” weight loss. The compound also demonstrated maintenance efficacy, sustaining weight loss regardless of how it was initially achieved or the target weight reached.
Importantly for long-term adherence, preclinical signals suggest a favorable tolerability profile, including reduced potential for nausea. Additional readouts indicated benefits across metabolic comorbidities, reinforcing ENV-308’s positioning as more than a cosmetic weight-loss intervention.
To guide its expanding metabolic portfolio, Enveda has tapped a seasoned leader with deep roots in genetics-driven prevention. Sarwar joins the company from Novo Nordisk, leading efforts to predict and prevent obesity. His prior roles include senior leadership positions at Eisai and Pfizer, spanning cardiometabolic genetics and neurodegenerative disease discovery.
At Enveda, Sarwar will oversee global strategy across prevention, early metabolic risk intervention and long-term maintenance, ensuring that clinical development aligns with the real-world needs of patients, clinicians and health systems.
The prominent leader emphasized that the upcoming phase of metabolic health would be characterized by what patients are able to sustain over several years rather than just a few months.
He further noted that the potential for metabolic longevity lies in a prevention-oriented approach to care that aims to protect healthspan and help individuals maintain their well-being for decades.
“ENV-308’s unique preclinical profile supports this ambition, including the opportunity to deliver effective solutions at the scale needed for global health equity. I am excited to help build the evidence required to bring a durable, real-world and scalable solution to people and patients,” Sarwar added.
For investors tracking the obesity space, Enveda’s approach stands out for its emphasis on oral delivery, durability and prevention – attributes increasingly seen as critical to managing the long-term economic and clinical burden of metabolic disease.
By pairing regulatory progress with leadership expertise rooted in prevention science, the company is positioning ENV-308 not just as another weight-loss candidate, but as a potential pillar of metabolic longevity care.
As Phase 1 data emerge, attention will turn to whether ENV-308’s preclinical promise can translate into human outcomes, and whether Enveda can carve out a differentiated role in one of biotech’s most competitive areas.
